Impact Of High Fasting Plasma Glucose In The Clinical Outcome Of Patients With Advanced Nsclc With Pd-L1 >= 50% Treated With Frontline Pembrolizumab

S. Llop Serna, E. Puig,R. Palmero,J. Brenes,N. Vilarino,J. C. C. Ruffinelli,C. Mesia Barroso,J. Saldana Canada,M. Jove Casulleras,I. Brao Perez,M. Arellano, F. N. Luciano Mateo,I. Peiro Martinez, C. Munoz Pinedo,E. Nadal

ANNALS OF ONCOLOGY（2021）

引用 0|浏览22

暂无评分

摘要

Hyperglycemia is associated with poor outcome in patients (pts) with curable non-small cell lung cancer (NSCLC), but its role in pts with advanced NSCLC is unknown. About a third of patients with PD-L1 ≥ 50% will experience early progression to pembrolizumab and markers predicting unfavorable outcome are urgently needed.

查看译文

关键词

plasma glucose,frontline pembrolizumab,clinical outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要